Skip to main content

ImmunoGen, Inc. (IMGN)

NASDAQ: IMGN · IEX Real-Time Price · USD
5.90 -0.20 (-3.28%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap1.19B
Revenue (ttm)136.64M
Net Income (ttm)-55.78M
Shares Out199.89M
EPS (ttm)-0.29
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume567,279
Open6.12
Previous Close6.10
Day's Range5.90 - 6.12
52-Week Range3.46 - 10.88
Beta1.32
AnalystsBuy
Price Target9.79 (+65.9%)
Est. Earnings DateNov 5, 2021

About IMGN

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, ...

IndustryBiotechnology
IPO DateNov 16, 1989
CEOMark Enyedy
Employees79
Stock ExchangeNASDAQ
Ticker SymbolIMGN
Full Company Profile

Financial Performance

In 2020, ImmunoGen's revenue was $132.30 million, an increase of 60.81% compared to the previous year's $82.27 million. Losses were -$44.37 million, -57.39% less than in 2019.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ImmunoGen stock is "Buy." The 12-month stock price forecast is 9.79, which is an increase of 65.93% from the latest price.

Price Target
$9.79
(65.93% upside)
Analyst Consensus: Buy

News

ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors

2 days ago - Business Wire

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1 month ago - Business Wire

ImmunoGen (IMGN) Q2 Loss Narrower Than Expected, Revenues Lag

ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates.

1 month ago - Zacks Investment Research

ImmunoGen (IMGN) Reports Q2 Loss, Misses Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 16.67% and -10.44%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results

1 month ago - Business Wire

Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results

2 months ago - Business Wire

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - Business Wire

Why Is ImmunoGen (IMGN) Down 8.7% Since Last Earnings Report?

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference

4 months ago - Business Wire

ImmunoGen Announces Mature Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avasti...

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Mature Data from FORWARD II Study of Mirvetuximab with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status

4 months ago - Business Wire

ImmunoGen (IMGN) Q1 Earnings Top, Pivotal Studies Delayed

ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. Meanwhile, data readouts from pivotal studies on lead candidate get delayed due to COVID-19.

4 months ago - Zacks Investment Research

ImmunoGen (IMGN) Reports Q1 Loss, Misses Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 10.53% and -7.15%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Immunogen: Q1 Earnings Insights

Shares of Immunogen (NASDAQ:IMGN) decreased 1.8% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were unchanged 0.00% over the past year to ($0.17), whi...

4 months ago - Benzinga

ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results

4 months ago - Business Wire

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - Business Wire

ImmunoGen Announces Conference Call to Discuss Its First Quarter 2021 Operating Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its First Quarter 2021 Operating Results

4 months ago - Business Wire

ImmunoGen Presents Preclinical Data on IMGC936 at the AACR Virtual Annual Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Preclinical Data on IMGC936 at the AACR Virtual Annual Meeting

5 months ago - Business Wire

Why Is ImmunoGen (IMGN) Up 9.2% Since Last Earnings Report?

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock?

6 months ago - Zacks Investment Research

ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference

7 months ago - Business Wire

ImmunoGen (IMGN) Q4 Earnings & Sales Top, Pipeline on Track

ImmunoGen (IMGN) reports encouraging fourth-quarter results. Top-line data readout from pivotal studies on its lead candidate, mirvetuximab soravtansine, remains on track.

7 months ago - Zacks Investment Research

How ImmunoGen Trounced Analysts' Q4 Revenue and Earnings Estimates

The company can thank its partner, Jazz Pharmaceuticals.

7 months ago - The Motley Fool

Recap: Immunogen Q4 Earnings

Shares of Immunogen (NASDAQ:IMGN) moved higher by 2.9% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 433.33% year over year to $0.16, which ...

7 months ago - Benzinga

ImmunoGen (IMGN) Surpasses Q4 Earnings and Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 500.00% and 69.54%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

ImmunoGen Reports Recent Progress and 2020 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and 2020 Financial Results

7 months ago - Business Wire